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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) comprises majority of pancreatic neoplasm and
remains to pose an enormous challenge to patients and clinicians with the worst survival rate
among all major malignancies. PDAC is the fourth leading cause overall and second leading
cause of gastrointestinal cancer death in the United States. [1] It is estimated that 45,220 new
cases and 38,460 deaths would result from pancreatic cancer in the United States in 2013. [2]
Worldwide, there were more than 277,668 new cases and 266,029 deaths from this cancer in
2008. [3] In comparison to other major malignancies such as breast, colon, lung and prostate
cancers with their respective 89, 64, 16, 99% 5-yr survival rate, PDAC at 6% is conspicuously
low[2]. For PDAC, the only curative option is surgical resection, which is applicable in only
10–15% of patients due to the common discovery of late stage at diagnosis. [4] In fact, PDAC
is notorious for late stage discovery as evidenced by the low percentage of localized disease
at diagnosis, compared to other major malignancies: breast (61%), colon (40%), lung (16%),
ovarian (19%), prostate (91%), and pancreatic cancer (7%) [5].
With the high contribution of late-stage discovery and general lack of effective medical
therapy, one critical approach in reversing the poor outcome of pancreatic cancer is to develop
an early detection scheme for the tumor. Despite the poor prognosis of the disease, for those
who have undergone curative resection with negative margins, the 5-year survival rate is 22%
in contrast to 2% for the advanced-stage with distant metastasis. [6, 7] An earlier diagnosis
with tumor less than 2 cm (T1) is associated with a better 5-yr survival of 58% compared to
17% for stage IIB PDAC. [8] Ariyama, et al showed 100% survival in 79 patients with tumors
less than 1 cm undergoing curative resection. [9] Also as the recent report indicates, the
estimated time from the transformation to pre-metastatic growths of pancreatic cancer is
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approximately 15 years [10], there is a wide potential window of opportunity to apply
developing technologies in early detection of this cancer.
In this article, we will discuss the current status of the PDAC cancer detection/diagnostic
modalities and ongoing research endeavors in developing early detection schemes for this
devastating disease.
2. Current status of PDAC cancer detection and diagnosis — Imaging-based
tests
As clinical symptoms of early stages of PDAC is commonly nonspecific and as currently
available clinical markers such as CA19-9, CEA, have low sensitivity and specificity at early
stage disease 11, clinicians who are suspecting the occurrence of PDAC in a patient rely heavily
on diagnostic imaging tests for assessment of a potential tumor.
Over the past few decades, endoscopic ultrasound (EUS) has proven itself to be a superior
imaging modality for detection of a small or early-stage pancreatic neoplasm as compared to
others such as transabdominal ultrasound (US), computed tomography (CT), endoscopic
retrograde cholangiopancreatography (ERCP), magnetic resonance imaging (MRI), positron
emission tomography (PET) and angiography. [12, 13, 14, 15, 16, 17] Yasuda and Rosch had
initially demonstrated the superiority of EUS in detection of pancreatic lesions <2 cm in
diameter. [12, 18] More recently, De Witt, et al had verified the superiority of EUS as compared
to multi-detector CT scan. In their study, the sensitivity of endoscopic ultrasonography (98%
[95% CI=91% to 100%]) for detecting a pancreatic mass (of any size) was significantly greater
than that of CT images (86% [CI=77% to 93%]; p=0. 012) [13]. In another study, Khashab, et al
demonstrated that the sensitivity of EUS in detecting pancreatic tumor was greater than CT
(91. 7% vs. 63. 3%; P=. 0002) and particularly for pancreatic neuroendocrine tumors (84. 2% vs.
31. 6%; P=. 001), which commonly consist of smaller pancreatic lesions. Furthermore, EUS
detected 20 of 22 CT-negative tumors (91%) in this study. [14] In a retrospective study
published by Klapman, et al, EUS diagnosis of pancreatic cancer was found to be highly specific
with a negative predictive value (NPV) of 100%. Following the EUS examination, no work-up
was required in 119/135 (88%) of patients. [15]
A challenge in imaging-based studies remains to be distinguishing pancreatic malignant
lesions from chronic inflammatory changes. Bhutani, et al reviewed 20 cases of missed
pancreatic cancer on EUS evaluation in a multicenter retrospective study. They found missed
neoplasms in patients with chronic pancreatitis, recent episodes of acute pancreatitis, diffusely
infiltrating carcinoma, or a prominent ventral/dorsal split. [16] Conventional power Doppler
EUS has some utility in this regard; Sa`ftoiu, et al in a study of 42 patients showed that absence
of power Doppler signals inside a suspicious pancreatic mass had a sensitivity of 93% and a
specificity of 77%, with an accuracy of 88% in the diagnosis of pancreatic cancer. In the presence
of peripancreatic collaterals, the sensitivity and specificity for the diagnosis of pancreatic
cancer rose to 97% and 92%, respectively, with an accuracy of 95%. [17]
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Elastography is a newer EUS imaging modality used for the real-time visualization of tissue
elasticity, and it demonstrates the difference in tissue stiffness between diseased and normal
regions. [19, 20] Tumor is commonly stiffer than the normal surrounding tissue, and this
characteristic is utilized in the determination of presence of neoplastic lesion, including
pancreatic cancer. [21] Giovannini, et al tested this method for the differential diagnosis of
benign and malignant lymph nodes and focal pancreatic masses in a small study of 49 patients
and showed a sensitivity and specificity of 100% and 67% for the diagnosis of malignant
pancreatic lesions. They concluded that this technique could be used to guide biopsy sampling
for PDAC diagnosis. [22]
Contrast enhancing agents such as galactose microparticles (Levovist) and sulfur hexafluoride
microparticles (SonoVue, a second-generation agent) have been applied in the diagnosis of
pancreatic malignancy by assessing the differential vascular perfusion in the pancreatic mass.
[23, 24] Hocke, et al reported the differentiation of inflammation versus pancreatic carcinoma
based on perfusion characteristics of the microvessels. [25] By using the contrast-enhanced
EUS, the sensitivity of the diagnosis of malignant pancreatic lesion with chronic inflammatory
pancreatic disease increased to 91. 1% (in 51 of 56 patients) and the specificity to 93. 3% (in 28
of 30 patients) in comparison to conventional EUS sensitivity and specificity of 73. 2% and 83.
3%, respectively. Applicability of an additional modality such as the low mechanical index
contrast-enhanced imaging (wide band harmonic imaging) technique has been reported in 6
patients by Dietrich, et al with good arterial, portal venous and parenchymal contrast en‐
hancement. [26] Further study for accuracy of this particular diagnostic testing is anticipated.
2.1. EUS-guided Fine Needle Aspiration (FNA) in pancreatic cancer
Studies  have  shown  that  the  accuracy  of  EUS-FNA  is  better  compared  to  both  ERCP
brushings and CT-or transabdominal ultrasound-guided FNA for the PDAC diagnosis. [27,
28] EUS-FNA has reported success rates of 90–95%, with an overall sensitivity and specificity
of 90% and near-100%, respectively. [29, 30, 31, 32] The main advantage of EUS-guidance
is the ability to visualize and target small pancreatic masses. Lesions of 5 mm or less could
be visualized and sampled, which might not have been accessible or identifiable by other
imaging modalities. [33] Krishna, et al, in a review of 213 patients, found EUS-guided FNA
to be highly accurate for diagnosing malignancy in patients with a focal pancreatic lesion
noted on CT scan/MRI without obstructive jaundice.  EUS-FNA had 97.  6% accuracy for
diagnosing a malignant neoplasm, with 96. 6% sensitivity, 99. 0% specificity, 96. 2% negative
predictive value,  and 99.  1% positive predictive value.  [34]  Agarwal,  et  al  compared 81
consecutive  patients  who  underwent  EUS,  EUS-FNA  and  spiral  CT  with  a  multiphasic
pancreatic protocol for clinical suspicion of PDAC. They showed that the accuracy of spiral
CT, EUS, and EUS-FNA was 74% (n=60/81, CI 63-83%), 94% (n=76/81, CI 87-98%), and 88%
(n=73/81, CI 81-96%), respectively, for detecting pancreatic cancer. In their study, absence
of a focal lesion on EUS reliably excluded pancreatic cancer irrespective of clinical presen‐
tation (NPV 100% n=5/5, CI 48-100%). [35]
From a practical standpoint, tumor cell seeding of the FNA tract is rare and only a few EUS
cases have been reported. Micames, et al in their study demonstrated that EUS-FNA has a
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lower risk of peritoneal contamination with malignancy than CT-guided FNA (2. 2% versus
16. 3%), respectively. [36] This is a potential complication of EUS-FNA that would need to be
kept in mind by clinicians when FNA sampling of a lesion is being considered. [37, 38]
3. Molecular markers & pancreatic cancer
In order to enhance the diagnostic accuracy of PDAC, molecular markers on EUS-FNA samples
have been evaluated in recent years. Utilities of DNA mutations such as k-ras and loss of
heterozygosity are being reported as potential surrogate markers of the malignancy. [39, 40]
In a recent study, Takahashi, et al assessed k-ras point mutations in PDAC and chronic focal
pancreatitis samples obtained by EUS-FNA. [41, 42, 43] The study revealed the presence of
point mutations of k-ras in 74% of patients with PDAC compared to no mutations in chronic
focal pancreatitis. In another study, Tada, et al reported a high (more than 2% of total k-ras
gene) mutation rate in 20 of 26 cases of EUS-FNA specimens (77%) and in 12 of 19 cases of
pancreatic juice (63%) in PDAC. [44] However, the presence of k-ras mutations in chronic
pancreatitis and premalignant conditions such as intraductal papillary mucinous neoplasm as
well as lack of such mutations in 20% of pancreatic cancer has limitations for using this test
solely as a diagnostic tool. Other studies analyzing p53 by immunohistochemistry, [45]
telomerase activity with a ribonucleoprotein enzyme, [46] and a broad panel of microsatellite
allele loss markers demonstrated similar results. [47] In the presence of inconclusive EUS-FNA
cytology, molecular markers could complement EUS-FNA cytology results to help establish
the diagnosis of malignancy.
4. Select population-based research for early detection scheme
development
4.1. Screening for pancreatic cancer in high-risk individuals
Currently, a general population-screening program for PDAC is not cost-effective because of
low relative disease incidence and non-availability of simple, cheap, highly accurate non-
invasive tests. The main aim of the screening is to detect clinically significant precursor lesions
or early stage PDAC. However, since the overwhelming majority of premalignant lesions and
small pancreatic cancers are asymptomatic, we do not yet have a routinely utilized surrogate
marker to identify a subset population for screening. Consequently, as one of the approaches
in investigating the genetic risks, research has focused on investigating a subset of individuals
with a higher-risk for PDAC development in order to elucidate the genetic predilection. Up to
10% of pancreatic cancer patients have a familial basis and they have increased risk of
developing both pancreatic and extra-pancreatic malignancies. [48, 49, 50, 51, 52] Classic
categorization of high-risk patients are based on the highly associated genetic risks defined as
those who are either members of a family with at least two first-degree relatives affected by
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the disease or are part of an inherited pancreatic cancer syndrome with a known genetic
mutation. (Table 1)
Syndrome Inheritance Gene Mutation Risk of PDAC
Peutz-Jeghers
syndrome [53]
Autosomal
dominant (AD)
STK11/LKB1 Standardized Incidence Ratio (SIR) = 132
Hereditary Pancreatitis
[54, 55, 56]
AD PRSS1
SPINK1
Odds ratio (OR) = 69. 9
Familial atypical
multiple mole
melanoma syndrome
[57, 58, 59]
AD CDKN2A SIR=13-38
Hereditary breast-
ovarian cancer
syndrome [60, 61, 62,
63, 64, 65, 66]
AD BRCA2
BRCA1
BRCA2: OR=3. 5-10-fold increased risk
BRCA1: OR=2. 26 times average population
Lynch syndrome
[59, 67]
AD MLH1, MSH2, MSH6
or PMS2
SIR = up to 8. 6
Cystic fibrosis [68] Autosomal
recessive
CFTR OR = 5. 3-6. 6
Table 1. PDAC related genetic syndromes
4.1.1. Familial pancreatic cancer
Familial pancreatic cancer (FPC) cohort is distinguished by individuals with a strong family
history of PDAC-i. e. with the cancer in at least two first-degree relatives and individuals with
three or more affected family members (one of whom must be a first-degree relative) – and is
considered to be high-risk and a candidate for screening programs. [69, 70, 71] Currently, the
genetic basis for most cases of FPC is not fully understood. However, various studies have
demonstrated the presence of a germline mutation in the BRCA2 gene [61, 62, 63, 64], associ‐
ation of BRCA1 [72], paladin gene mutation [73] and involvement of other genes: apolipopro‐
tein A4, CEA, keratin 19, stratifin (14-3-3σ), trefoil factor, and calcium binding protein S100 A6
[74, 75] in FPC, and more recently identification of PALB2, [76] as a pancreatic cancer suscept‐
ibility gene. These facts suggest that multiple and heterogeneous factors are likely at play for
the genesis of PDAC in this subset.
Analysis of the PDAC kindred data from Johns Hopkins’ National Familial Pancreas Tumor
Registry (NFPTR) has demonstrated that the relative risk of PDAC in persons with two affected
first-degree relatives is 6. 4% and the cumulative life-time risk is 8%-12%; in individuals with
three affected first-degree relatives, the relative risk for PDAC increases to 32% and the
cumulative life-time risk to 16%-32%. [77] Tersmette, et al in their analysis of the NFPTR found
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an 18-fold increase in risk of PDAC, and an estimated lifetime risk of 9%-18% in the group. [78]
Brune, et al in their recent article reported a higher risk of PDAC among members of FPC
kindred with a younger age of onset (age < 50 years). [79] Rulyak, et al in another study found
smoking as a strong risk factor in FPC kindred, particularly among males and those under age
50. This risk increases by 2. 0-3. 7 times over the inherited predisposition and lowers the age
of onset by 10 years. [80] A computer-based risk assessment tool, PancPRO, has been developed
and is available for calculating the risk assessment for individuals with familial pancreatic
cancer (http://www4. utsouthwestern. edu/breasthealth/cagene/default. asp). [81]
4.1.2. Screening modalities & the current screening programs
Most of the screening programs have tried to use biomarkers complemented by imaging tests
to identify the early lesions. As stated earlier, a commonly used marker, CA19-9, is neither
specific nor sensitive independently for reliable detection of early pancreatic cancer or
pancreatic precursor lesions. Kim, et al in their studies found only 0. 9% positive predictive
value using a cut-off value of 37 U/mL. [82] Recently, many biomarkers have been investigated
including MIC-1, CEACAM-1, SPan1, DUPAN, Alpha4GNT, and PAM4, but none is validated
for routine clinical use. [83] In another approach, elevated fasting-glucose level has been shown
to be a marker for early cancer in sporadic cases [84] and is currently used by the EUROPAC
study in high-risk individuals with molecular analysis of pancreatic juice for the k-ras and p53
mutations in addition to p16 promoter methylation status.
Multiple  international  programs  exist  that  screen  for  pancreatic  cancer  in  high-risk
individuals in a research setting. “Cancer of the Pancreas Screening Study” (CAPS study),
led by John Hopkins University, is the largest screening program that involves 24 Ameri‐
can Centers of Excellence. To date, three studies, CAPS 1, CAPS 2 and CAPS 3, have been
completed. (Table 2)
In the CAPS 1 study, thirty-eight patients were studied; 31 (mean age, 58-yr; 42% men) from
a kindred with > 3 affected with pancreatic cancer; 6 from a kindred with 2 affected relatives,
and 1 was a patient with Peutz-Jeghers syndrome (PJS). Six pancreatic masses were found by
EUS: 1 invasive ductal adenocarcinoma, 1 benign intraductal papillary mucinous neoplasm, 2
serous cystadenomas, and 2 nonneoplastic masses. In this study, the diagnostic yield of
screening was 5. 3%. [85] In the CAPS 2 study a 10% diagnostic yield of screening for pre-
invasive malignant lesions was found. [86] In this study, screening was performed using
annual EUS and CT. If an abnormality was detected, ERCP was offered. Seventy-eight high-
risk patients (72 from a FPC kindred, 6 PJS) and 149 control patients were studied. Of these,
eight patients had confirmed pancreatic neoplasia by surgery or FNA (10% yield of screening);
6 patients had benign intraductal papillary mucinous neoplasms (IPMNs), 1 had an IPMN that
progressed to invasive ductal adenocarcinoma, and 1 had high-grade pancreatic intraepithelial
neoplasia (PanIN-3). The CAPS 3 study was a multicenter prospective, controlled cohort study
that involved annual screening using EUS and MRCP, MRI with secretin and a panel of
candidate DNA and protein markers in serum and pancreatic juice (CA19-9, macrophage
inhibitory cytokine-1 (MIC-1), DNA hypermethylation, and k-ras gene mutations) as indicators
of pancreatic neoplasm. Over 200 patients were enrolled over a three-year period. The study
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has recently been completed and the results on the detection modality comparison demon‐
strate that the EUS has the highest rate of detection of early neoplastic changes in up to 42. 6%
of the asymptomatic high-risk group. [87]
In another study from the University of Washington, high-risk familial cohorts were screened
using EUS and beginning 10 years prior to the earliest PDAC death in the family. If EUS was
normal, then they were followed-up with a repeat EUS at 2-3 year intervals. In case of abnormal
EUS findings, they were referred for ERCP and if abnormalities were noted, patients were
offered surgical intervention. [88] Patients with abnormal EUS, but normal ERCP were offered
annual EUS. Out of 75 subjects screened, 15 had abnormalities on EUS and ERCP and went to
surgery. The histology revealed premalignant lesions in all: PanIN-3 in 10 cases and PanIN-2
in five. [89] This study gave a diagnostic yield of 13% (10 out of 75) for detecting PanIN-3
premalignant lesions. One patient developed unresectable pancreatic cancer while under
annual surveillance.
In Europe, the European Registry for Familial Pancreatic Cancer and Hereditary Pancreatitis
(EUROPAC) incorporated EUS, ERCP and molecular analysis of the pancreatic juice looking
for early mutations (p53, k-ras, and p16), and the results are pending. A German Study (FaPaCa)
enrolled 76 patients in a screening program using yearly EUS, MRCP and laboratory tests
(genetic analysis of CDKN2a and BRCA2 genes, CA19-9 and CEA). Any suspicious lesion was
evaluated with EUS ± FNA after 6 weeks and a close follow-up at 12 weeks. If an abnormality
was detected, the patient underwent operative exploration with intraoperative ultrasound,
limited pancreatic resection with frozen section, and if cancer was detected, total pancreatec‐
tomy was performed. Ten solid lesions were seen on EUS as compared to only seven detected
by MRCP. Out of the seven MRCP-detected lesions, six had limited resections and the histology
showed one patient with PanIN-3, one with PanIN-2, one with PanIN-1, and three were benign
lesions. These results gave a diagnostic yield of 1. 3% in detecting PanIN-3. [90] A recent study
from the Netherlands that used only EUS as the first screening modality in 44 high risk
asymptomatic subjects showed a 7% diagnostic yield for asymptomatic cancers and a 16%
diagnostic yield for premalignant lesions (IPMN-like lesions). [91]
Study CAPS1 CAPS2 CAPS3 U of Washington FaPaCa Dutch Study
Diagnostic
Yield*
5. 3
(2/38)
10
(8/78)
42
(92/216)
13%
(10/75)
1. 3
(1/76
23
(10/44)
*Represents finding of abnormal imaging such as mass (solid, cyst) or abnormal duct
CAPS: Cancer of the Pancreas Screening Study; FaPaCa: Familial Pancreatic Cancer Study
Table 2. Results of screening programs for pancreatic cancer in high-risk groups
Questions remain regarding the cost-effectiveness of these screening modalities. Rulyak, et al
reported that screening was cost-effective with an incremental cost-effectiveness ratio of
$16,885/life-year saved (assuming a 20% incidence of dysplasia and a 90% sensitivity of EUS
and ERCP). [92] Rubenstein, et al performed a systematic review, and created a Markov model
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for 45-year-old male first-degree relatives, with findings of chronic pancreatitis on screening
by EUS. They compared 4 strategies: do-nothing, prophylactic total pancreatectomy (PTP),
annual surveillance by EUS, and annual surveillance with EUS and fine needle aspiration. In
the do-nothing strategy, the lifetime risk of cancer was 20% and it provided the greatest
remaining years of life, the lowest cost, and the greatest remaining quality-adjusted life years
(QALYs). PTP provided the fewest remaining years of life and QALYs. Screening with EUS
provided nearly identical results to PTP, and screening with EUS/FNA provided intermediate
results between PTP and the do-nothing approach. Total pancreatectomy provided the longest
life expectancy if the lifetime risk of PDAC was at least 46% and provided the most QALYs if
the risk was at least 68%. [93] Further assessment of the models in other clinical scenarios with
developing technology would be in order.
5. Future of pancreatic cancer screening
Current EUS screening programs have demonstrated that the endoscopic evaluation can detect
premalignant lesions and early cancers in certain subsets of high-risk groups, although cost-
effectiveness still remains an issue. However, as the majority of PDAC diagnosis is given to
patients who develop the disease sporadically without a recognized genetic abnormality, the
application of this modality for PDAC detection screening is very limited for the general adult
population. In order to further delineate and expand the at-risk subset, there is a strong need
for novel surrogate markers which allow identification of the group with increased PDAC risk
for whom the endoscopic/imaging-based screening strategy could be applied.
5.1. Select population based research — Identification of a higher-PDAC-risk group
A practical approach for further selection of the potential screening population is to focus on
selective clinical parameters that would be used to characterize the subset of the general
population at increased PDAC risk. For instance, based on the epidemiological evidence, such
clinical parameters include incidence of hyperglycemia or diabetes, which are being noted in
50-80% of pancreatic cancer patients [94, 95, 96, 97, 98]. Though this subset does not encompass
all PDAC patients, this group includes a much larger proportion of PDAC patients whom we
may select further to screen for PDAC. Similarly, patients with a history of chronic pancreatitis
or obesity are reported to have increased PDAC risk during their lifetime [99, 100, 101, 102,
103, 104]. Animal studies investigating effects of diet-induced obesity in a PDAC mouse model
demonstrated increased occurrence of pancreatic inflammation and accelerated pancreatic
neoplastic changes, supporting the association of obesity and pancreatic inflammation and
PDAC risks. [105, 106] Considering the millions of patients who are being diagnosed with
diabetes, chronic pancreatitis, or obesity annually as opposed to PDAC, further refinement of
screening of these patient groups is critically needed to justify developing a larger scale
screening protocol in the future.
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5.2. Translational research — Application of systems biology approach
As we continue to translate the advancement of biological understanding of PDAC, we
strongly anticipate that better biomarkers will become available in the near future that would
identify higher-risk individuals within the general population for developing early-stage
PDAC. Aside from the previously referenced reports, many genetic, epigenetic, proteomics,
metabolomics, glycomics findings-utilizing systems biology approaches-are being considered
for biomarker identifications for PDAC detection. In transcriptomics analysis of blood
biomarkers in PDAC-associated diabetes mellitus, for example, gene expression analysis in
blood from PDAC patients with new-onset diabetes versus long-term or no history of diabetes
revealed a set of differentially expressed genes such as vanin-1 and matrix metalloproteinase
9, which are able to discriminate the PDAC group with sensitivity of 92% and specificity of
84%. [107] From proteomics analyses, shotgun approaches with highly accurate mass spec‐
trometric assays demonstrated such proteins as apolipoprotein CIII [108], mannose-binding
lectin 2, myosin light chain kinase 2 [109], CXC chemokine ligand 7 [110], TIMP1-ICAM1 [111],
and alpha-1 antitrypsin [112] as candidate biomarkers of PDAC. These and other candidate
biomarkers need to be validated with larger populations with appropriate control groups.
With the technological advancement in the mass spectrometric techniques over the recent
decades and resumed interest in the cancer-associated metabolic abnormality, [113, 114]
application of metabolomics in the cancer field has attracted more attention. Metabolomics
allows for elucidating the complete set of metabolites or low-molecular-weight intermediates
in the physiological, developmental or pathological state of the cell, tissue, organ, or organism.
[115] And metabolomics study of PDAC detection biomarkers will seek identification of a set
of small molecules or metabolites (or chemical intermediates) that are potential discriminators
of developing PDAC and the controls. Recent reports from our group as well as others have
demonstrated specific small molecules such as amino acids, bile acids, and various lipids and
fatty acids as potential candidates for PDAC biomarkers. [116, 117, 118, 119] Since a metabo‐
lome represents a current physiological readout of the biochemical state in an individual’s
biofluid or tissue space and as the functional end-product of the varying signals from the
genome and proteome, it reflects the up-to-date phenotypic state of an individual in the
presence of environmental stimuli. Thus, metabolomics data potentially provides additional
temporal information to cancer risks derived from gene-based PDAC risk data alone. Since
many enzymes in a metabolic network determine metabolites’ concentrations and nonlinear
quantitative relationship from the genes to the proteome and metabolome levels exist, a
metabolome cannot be easily decomposed to a specific single marker, which will designate the
disease state. [120] So, in order to delineate a physiological or pathological state, multiple
metabolomic features might be required for accurate depiction of such a state as a developing
cancer. In addition, future studies are anticipated to incorporate further cancer systems’
biological knowledge, including multi-omics-based analyses for optimal designation of PDAC
biomarkers, which would be utilized in conjunction with a clinical-parameter-derived
population subset for establishing the PDAC screening population. Subsequently, further
validation studies for the PDAC biomarkers need to be performed.
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6. Conclusion
Current imaging-based detection and diagnostic methods for PDAC is effectively providing
answers to clinical questions raised for patients with signs or symptoms of suspected pancre‐
atic lesions. However, the endoscopic/imaging-based schemes are currently limited in
applications to early PDAC detection in asymptomatic patients, aside from a relatively small
group of known genetically high-risk groups. There is a high demand for developing a method
of selecting distinct subsets among the general population for implementing the endoscopic/
imaging screening test effectively. Application of combinations of clinical risk parameters/
factors with the developing molecular biomarkers from translational science brings high hopes
of providing us with early PDAC detection markers, and developing effective early detection
screening scheme for the patients in the near future.
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